These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 11587553)
1. Hypothalamic hormones and cancer. Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553 [TBL] [Abstract][Full Text] [Related]
2. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin]. Schally AV An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy targeted to cancers through tumoral hormone receptors. Schally AV; Nagy A Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601 [TBL] [Abstract][Full Text] [Related]
4. New treatment approaches for prostate cancer based on peptide analogues. Stangelberger A; Schally AV; Djavan B Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818 [TBL] [Abstract][Full Text] [Related]
5. New approaches to the therapy of various tumors based on peptide analogues. Schally AV Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250 [TBL] [Abstract][Full Text] [Related]
6. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Schally AV; Redding TW; Comaru-Schally AM Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868 [TBL] [Abstract][Full Text] [Related]
7. [History of clinical studies on hypothalamic hormone analogs in Mexico]. Schally AV; González Bárcena D Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307 [TBL] [Abstract][Full Text] [Related]
8. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045 [TBL] [Abstract][Full Text] [Related]
9. Peptide analogs in the therapy of prostate cancer. Schally AV; Comaru-Schally AM; Plonowski A; Nagy A; Halmos G; Rekasi Z Prostate; 2000 Oct; 45(2):158-66. PubMed ID: 11027415 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665 [TBL] [Abstract][Full Text] [Related]
11. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Pinski J; Halmos G; Szepeshazi K; Schally AV Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552 [TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
13. The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers. Szepeshazi K; Block NL; Schally AV Horm Mol Biol Clin Investig; 2010 Jan; 1(3):103-10. PubMed ID: 25961976 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527 [TBL] [Abstract][Full Text] [Related]
15. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Schally AV; Nagy A Life Sci; 2003 Apr; 72(21):2305-20. PubMed ID: 12639697 [TBL] [Abstract][Full Text] [Related]
16. Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro. Krebs LJ; Wang X; Nagy A; Schally AV; Prasad PN; Liebow C Int J Oncol; 2002 Dec; 21(6):1325-9. PubMed ID: 12429984 [TBL] [Abstract][Full Text] [Related]
17. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Liu SV; Schally AV; Hawes D; Xiong S; Fazli L; Gleave M; Cai J; Groshen S; Brands F; Engel J; Pinski J Clin Cancer Res; 2010 Sep; 16(18):4675-80. PubMed ID: 20670943 [TBL] [Abstract][Full Text] [Related]
18. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271 [TBL] [Abstract][Full Text] [Related]